Colorectal Cancer

For patients whose colorectal cancer has spread to the liver, and confirmed by computed tomography (CT), further imaging scans before surgery added little benefit when compared to patients who did not undergo further imaging.

Johanna Bendell, MD, discusses the rationale of a phase II trial looking at onartuzumab (MetMAb) and bevacizumab for patients with metastatic colorectal cancer (mCRC).

Treatment with the investigational oral agent TAS-102 significantly improved overall survival in a phase III trial for patients with heavily pretreated metastatic colorectal cancer.

The FDA's Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.

The blood-based colorectal cancer (CRC) screening test Epi proColon passed the scrutiny of the FDA's Molecular and Clinical Genetics advisory panel in a close 5-4 vote with 1 abstention in support of the claim that the test's benefits outweigh its risks

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses treatment options for patients with colorectal cancer who fail on oxaliplatin- and irinotecan-based chemotherapy.

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the future of the treatment of colorectal cancer.

Genetic counseling-including testing and risk assessment-is one of the most rapidly growing areas of oncology and has become the standard of care for patients with a personal and family history of breast, ovary, or colon cancer.

During the past 15 years, minimally invasive general surgery has rapidly expanded to include laparoscopic and robotic techniques for cholecystectomy, colectomy, gastric weight loss, and other procedures